We are international
Donate
TEXT SIZE   


ASH 2012: Dr. Berdeja - A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies
Jesus Berdeja, MD
Sarah Cannon Research Institute
Nashville, TN
12.03.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles